DEF: 180 Life Sciences Corp. Seeks Shareholder Approval for Reverse Stock Split, Massive Share Increase, and New Incentive Plans Amidst Nasdaq Listing Concerns

180 Life Sciences Corp. is calling its stockholders to an annual meeting to vote on critical proposals including a reverse stock split, a tenfold increase in authorized common stock, and new equity incentive plans, primarily aimed at maintaining its Nasdaq listing and attracting talent.

Summary

• The 2025 annual meeting of stockholders for 180 Life Sciences Corp. will be held virtually on Thursday, July 24, 2025, at 9:00 a.m. Pacific Time.
• Stockholders will vote on the re-election of two Class I directors: Lawrence Steinman, M.D. and Stephen H. Shoemaker.
• A proposal to adopt the Fourth Amendment to the 2022 Omnibus Incentive Plan will be voted on, which seeks to increase the maximum number of shares from 1,000,000 to 5,000,000 and introduce an evergreen provision for automatic annual increases of 10% of outstanding common stock from January 1, 2026, to January 1, 2032.
• Stockholders will also vote on the adoption of the 2025 Option Incentive Plan, reserving 1,000,000 shares for awards, with options already granted to executives and directors subject to shareholder approval for exercise.
• An advisory resolution on Named Executive Officer compensation will be presented for approval.
• A key proposal is an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock by a ratio of between one-for-four (1:4) to one-for-forty (1:40), with the exact ratio to be determined by the Board.
• Another significant proposal is to increase the authorized number of shares of common stock from 100,000,000 to 1,000,000,000.
• The appointment of M&K CPAs, PLLC as the independent auditors for the fiscal year ending December 31, 2025, will be ratified.
• The Board recommends voting 'FOR' all proposals.
• The company reported a net loss of $6,168,000 in 2024, a significant improvement from $19,935,000 in 2023 and $38,726,000 in 2022.
• As of June 30, 2025, there were 6,039,208 shares of common stock outstanding.
• The company's common stock has recently traded below $1.00 per share, with a closing price of $0.9038 on July 3, 2025, and an average closing price of $0.971 for the thirty trading days prior to the proxy statement date, indicating potential non-compliance with Nasdaq's minimum bid price requirement.
• The company previously effected a 1-for-20 reverse stock split on December 19, 2022, and a 1-for-19 reverse stock split on February 28, 2024, to regain Nasdaq compliance.
• Blair Jordan's compensation as CEO increased to $240,000 per year, effective January 1, 2025, with a potential increase to $350,000 upon completion of any material transaction, plus an incentive bonus of up to 100% of the fee.
• The company settled disputes with Elray Resources, Inc. and Luxor Capital, LLC, agreeing to acquire 1,318,000 shares of its common stock from Elray for $1,000,000, with $350,000 paid to Elray and $650,000 payable to Luxor by April 28, 2026, from future capital raises.
• The company settled litigation with Dr. Marlene Krauss, paying $50,000 cash and issuing 200,000 restricted common shares.
• The company settled litigation with Tyche Capital LLC and Ronald & Samantha Bauer, resulting in forgiveness of $81,720 in loans and $25,171 in accrued interest, and the cancellation of 2,385 shares of common stock previously held by Tyche.
• AmTrust International Underwriters DAC paid the company $2.27 million and a further $300,140 in reimbursement of fees advanced to Dr. Krauss and Mr. Hornig, with the company receiving $1,512,711 and $200,093 respectively after attorney fees.
• The company entered into a settlement agreement with AmTrust, agreeing to pay $250,000 cash and issue 509,707 common shares (valued at $575,000) to resolve ongoing litigation.
• Research and development expenses related to related parties increased by $87,055 (18%) from $480,777 in 2023 to $567,832 in 2024.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the company's persistent struggle with Nasdaq listing requirements, necessitating another reverse stock split and a massive increase in authorized shares, which signals significant dilution risk. While legal settlements are positive, the underlying financial health (ongoing net losses) and the need for such drastic corporate actions outweigh these, indicating a challenging outlook for investors.

Positives

• Net loss significantly decreased from $38.7 million in 2022 to $6.17 million in 2024, indicating improved financial performance.
• Settlement of multiple legal proceedings (Dr. Krauss, Tyche/Bauer, AmTrust) reduces legal overhead and uncertainty, with some settlements resulting in financial gains or debt forgiveness.
• The company received $1,712,804 in reimbursements from AmTrust for legal fees, improving cash position.
• The proposed Fourth Amendment to the 2022 Omnibus Incentive Plan and the 2025 Option Incentive Plan aim to attract and retain talent through equity compensation, which is crucial for a growth-oriented company.
• The Board of Directors has a strong independent Lead Director (Ryan Smith) and independent committees (Audit, Compensation, Nominating and Governance), indicating good corporate governance practices.
• The company has a Clawback Policy in place for erroneously awarded incentive-based compensation, aligning with SEC rules and promoting accountability.
• The company has an insider trading and anti-hedging policy to promote compliance and align management interests with shareholders.

Negatives

• The company's common stock has recently traded below $1.00 per share, indicating a risk of non-compliance with Nasdaq's minimum bid price requirement and potential delisting.
• The need for a reverse stock split (1:4 to 1:40) suggests persistent low share price issues and could further decrease liquidity.
• The proposal to increase authorized common stock from 100,000,000 to 1,000,000,000 shares represents a significant potential for future shareholder dilution.
• The company has a history of prior reverse stock splits (1-for-20 in Dec 2022, 1-for-19 in Feb 2024), which have not sustained the share price above Nasdaq's minimum, raising concerns about the long-term effectiveness of another split.
• If the company fails to meet the Minimum Bid Price Requirement within one year of the February 2024 reverse split, or if cumulative reverse splits exceed 1-to-250 within two years, it faces automatic delisting from Nasdaq.
• The company is actively discussing potential capital raises that 'may result in significant dilution to existing shareholders if completed'.
• Outstanding warrants (6,133,308 shares) and options (1,021,564 shares) represent substantial potential future dilution.
• The company's net loss, while improving, still indicates it is not profitable.
• Accounts payable to related parties were $684,181 as of December 31, 2024, indicating significant obligations to insiders.
• The company provides no assurance that Ronald and Samantha Bauer will indemnify the company against claims from Cambridge Capital Ltd. and Park Lane Capital, Ltd. for approximately $130,000 in loans, potentially exposing the company to further liabilities.

Risks

• Failure to maintain Nasdaq listing due to continued low bid price, leading to reduced liquidity and investor interest.
• The reverse stock split may not result in a sustained increase in share price, potentially leading to further delisting threats or a need for additional reverse splits.
• Significant dilution of existing shareholder value from the proposed increase in authorized shares and future capital raises.
• Increased trading costs and reduced liquidity for stockholders holding 'odd-lots' (less than 100 shares) after a reverse stock split.
• Potential for the increased proportion of authorized but unissued shares to be used as an anti-takeover defense, potentially against the interests of some shareholders.
• Ongoing legal liabilities or collection attempts from Cambridge Capital Ltd. and Park Lane, despite the Bauer settlement, if indemnification fails.
• Reliance on future capital raises to fund operations, with no assurance of favorable terms or availability.
• The 2025 Option Incentive Plan and Prior 2025 Option Awards will be unwound and cancelled if shareholder approval is not obtained by June 17, 2026, potentially impacting executive and director incentives.
• The company's ability to attract and retain key personnel is dependent on equity incentives, which could be hampered if share reserves are insufficient or plans are not approved.

Future Outlook

The company's future outlook is focused on maintaining its Nasdaq listing through a potential reverse stock split and securing additional capital. It aims to continue attracting and retaining key talent through enhanced equity incentive plans. The company anticipates growing its operations over the next several years and is actively discussing various capital raising options, which may lead to significant shareholder dilution. The Board reserves the right to abandon the reverse stock split or authorized share increase if it deems it not in the best interests of stockholders.

Management Comments

• "Your vote is very important. Even if you plan to attend the annual meeting, if you are a holder of record of voting stock please submit your proxy by mail, fax, Internet or telephone as soon as possible to make sure that your shares are represented at the annual meeting."
• "Our Board of Directors encourages your participation in 180 Life Sciences Corp.'s electoral process and, to that end, solicits your proxy with respect to the matters described in the Notice of Meeting and the proxy statement."
• "We look forward to seeing you on July 24, 2025. Your vote and participation in our governance is very important to us." Blair Jordan, Chief Executive Officer and Director.
• "The Board of Directors believes that because we only have five directors, that this leadership structure is the most effective and efficient for the Company at this time."
• "The Board believes that this leadership structure, including our strong independent Lead Director (Mr. Smith, as discussed below), best serves the Company and its stockholders at this time by leveraging executive leadership experience while providing effective independent oversight."
• "The Board expects that the Reverse Stock Split of our common stock will increase the market price of our common stock so that we are able to regain and maintain compliance with the Nasdaq minimum bid price listing standard."
• "We believe that granting our Board the authority to set the ratio for the Reverse Stock Split is essential because it allows us to take these factors into consideration and to react to changing market conditions."
• "We believe that the evergreen amendment will grant us greater flexibility to ensure consistent alignment between compensation and performance over the term of the 2022 OIP. This is particularly important as we anticipate growing our operations over the next several years and it is critical that we have sufficient shares to compensate anticipated new hires at market competitive levels."
• "The increase in the number of shares of common stock available for issuance is not being done for the purpose of impeding any takeover attempt."

Industry Context

The company operates in the biotechnology/pharmaceuticals sector, which is typically capital-intensive and requires significant R&D investment. The need for a reverse stock split and increased authorized shares suggests challenges in maintaining public market valuation and attracting capital, common issues for smaller biotech firms. The emphasis on equity incentive plans is standard for the industry to attract and retain specialized talent, especially when cash compensation might be limited. The ongoing legal disputes and high related-party expenses could indicate internal governance challenges or legacy issues that might deter new investors, contrasting with industry trends towards cleaner balance sheets and clear corporate structures.

Comparison to Industry Standards

• The company's repeated need for reverse stock splits (three proposed/effected within a few years) is highly unusual and generally indicates a struggle to maintain a sustainable stock price, which is below industry standards for stable public companies.
• The proposed increase in authorized shares from 100 million to 1 billion is a very large increase, potentially leading to significant dilution. While biotech companies often have large authorized share counts for future financing, a tenfold increase is substantial and could be viewed negatively compared to peers who manage capital more conservatively.
• The company's net loss, while improving, still places it in a pre-profitability stage common for early to mid-stage biotech companies, but the magnitude of past losses ($38.7M in 2022) is notable.
• The executive compensation structure, with a significant portion tied to long-term equity awards, aligns with industry standards for biotech, where long-term value creation is paramount. However, the specific figures and the context of past losses would need comparison to similarly sized and staged biotech companies to assess competitiveness and fairness.
• The company's corporate governance structure, including independent committees and a lead independent director, aligns with best practices for public companies, including those in the biotech sector.
• The ongoing legal proceedings and related-party transactions, while being resolved, suggest a higher level of internal complexity and historical issues compared to a typical, smoothly operating biotech firm. For example, the settlement with Dr. Marlene Krauss and the Tyche/Bauer litigation indicate past disputes that are not typical for a company focused solely on R&D and commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• Action Against Former Executive of KBL (Dr. Marlene Krauss): Company initiated legal action on September 1, 2021, for unauthorized monetary transfers, non-disclosure of liabilities, and improper share issuance, seeking over $11.2 million. Dr. Krauss filed counterclaims for alleged misstatements, failure to register shares, and unpaid promissory notes. Settled on February 21, 2025, with the Company paying $50,000 cash and issuing 200,000 restricted shares, and mutual dismissals with prejudice.
• Action Against the Company by Dr. Krauss: Dr. Krauss initiated legal action on August 19, 2021, seeking advancement of expenses for SEC investigation and other legal defense costs. Court ordered the Company to pay $714,557 in May 2023. Settled on February 21, 2025, as part of the broader settlement.
• Action Against Tyche Capital LLC: Company filed action on April 15, 2021, for breach of contractual obligations, claiming $6.7 million in damages. Court granted attachment order against Tyche's shares and later granted summary judgment in favor of the Company on liability. Settled on June 30, 2024, resulting in forgiveness of $81,720 in loans and $25,171 in accrued interest from Bauer Defendants, and cancellation of 2,385 Tyche shares.
• Action Against Ronald Bauer & Samantha Bauer: Company initiated legal action on February 25, 2022, for misappropriation of funds and stock, unauthorized sales, and improper travel expenses. Settled on June 30, 2024, as part of the Tyche settlement.
• Declaratory Relief Action Against the Company by AmTrust International: AmTrust filed action on June 29, 2022, seeking declaration that it was not obligated to reimburse the Company for fees advanced to Dr. Krauss and George Hornig. Company counterclaimed for bad faith breach, seeking $2 million. Court largely ruled in favor of the Company, ordering AmTrust to advance defense costs. AmTrust paid $2.27 million and $300,140 in reimbursements. Settled on April 6, 2025, with the Company paying $250,000 cash and issuing 509,707 common shares to AmTrust, and mutual releases.

Related Party Transactions

• Blair Jordan (CEO and Director): Provides services through Blair Jordan Strategy and Finance Consulting Inc., which he owns. His compensation increased to $240,000/year (potentially $350,000) plus bonuses. He also holds an irrevocable voting proxy for 43,166 shares from Dr. Woody, 200,000 shares from Dr. Krauss, and 1,318,000 shares from Elray Resources Inc. due to voting agreements.
• Eric R. Van Lent (Chief Accounting Officer): Provides services through EVL Consulting, LLC, which he owns, for $8,000/month for 10 hours/week, plus $200/hour for pre-approved excess hours.
• Prof. Sir Marc Feldmann (former Co-Executive Chairman): Received 57,328 shares of common stock and options to purchase 20,000 shares (exercise price $1.95) as part of a separation agreement for past services.
• Prof. Jagdeep Nanchahal: Consultant receiving 15,000 GBP/month (increasing to 23,000 GBP/month upon certain conditions) and previously received shares in lieu of cash bonuses (265 shares for GBP 217,337 and 161 shares for GBP 134,749).
• Prof. Lawrence Steinman (Director): Consulting agreement for $225,000/year, later reduced to $0 with accrued amounts waived, now receives non-executive director compensation.
• Elray Resources, Inc. (greater than 5% stockholder, controlled by Anthony Brian Goodman): Converted 1,000,000 Series B Preferred Stock into 1,318,000 common shares. Entered into a settlement agreement to sell back these 1,318,000 shares for $1,000,000 ($350,000 to Elray, $650,000 to Luxor). Also holds warrants to purchase 3,000,000 common shares at $1.68/share.
• Luxor Capital, LLC (controlled by Anthony Brian Goodman): Part of the Elray settlement, receiving $650,000 from future capital raises.
• Anthony Brian Goodman (father of former director Jay Goodman): Controls Elray Resources, Inc. and Luxor Capital, LLC, involved in the settlement agreement.
• Jay Goodman (former Director): Received $98,333.33 upon resignation, including board fees and an additional payment.
• Dr. James N. Woody (former CEO and Director): Received $50,000 cash and 25,000 fully-vested shares as part of a separation agreement. Later amended to terminate a $50,000 contingent bonus in exchange for 43,166 restricted shares and a voting agreement.
• Dr. Marlene Krauss (former CEO and Director of KBL Merger Corp. IV): Settled litigation by receiving $50,000 cash and 200,000 restricted shares, and entered into a voting agreement.
• Ronald Bauer & Samantha Bauer: Forgave $81,720 in loans and $25,171 in accrued interest as part of a settlement agreement.
• AmTrust Financial Services, Inc. (greater than 5% stockholder): Received 509,707 common shares (valued at $575,000) and a $250,000 cash payment as part of a litigation settlement.
• Accounts Payable Related Parties: $684,181 as of December 31, 2024, primarily due to officers and directors, and deferred compensation.
• Research and Development Expenses Related Parties: $567,832 in 2024, an 18% increase from $480,777 in 2023.

Stakeholder Impact

• Shareholders: Face significant potential dilution from the proposed increase in authorized shares and future capital raises. The reverse stock split aims to maintain Nasdaq listing, which could benefit liquidity, but also carries risks of further price decline and reduced liquidity for odd-lot holders. Voting agreements with large shareholders (Dr. Woody, Dr. Krauss, Elray) give Blair Jordan significant voting control over a portion of outstanding shares.
• Employees/Executives/Directors: Benefit from new and expanded equity incentive plans (2022 OIP amendment, 2025 Option Incentive Plan) designed to attract, retain, and motivate talent. Compensation agreements for current executives (Blair Jordan, Eric R. Van Lent) are detailed, and past separation agreements for former executives are disclosed.
• Creditors: Some related party payables are significant, and the company is working to resolve past financial obligations through settlements, which could improve its credit profile. However, the need for capital raises indicates ongoing financial needs.
• Customers/Suppliers: No direct impact mentioned, but the company's financial stability and ability to raise capital indirectly affect its operational continuity and ability to engage with external partners.
• Regulatory Authorities (SEC, Nasdaq): The company is actively addressing Nasdaq listing compliance issues through the proposed reverse stock split. Compliance with SEC rules, including clawback policies and insider trading policies, is emphasized.

Next Steps

• Hold the 2025 annual meeting of stockholders virtually on July 24, 2025, to vote on the proposed resolutions.
• If approved, the Board of Directors will determine the exact ratio for the reverse stock split (between 1:4 and 1:40) and implement it prior to July 24, 2026.
• If approved, the increase in authorized common stock to 1,000,000,000 shares will be implemented.
• If the 2025 Option Incentive Plan is not approved by stockholders by June 17, 2026, the plan and its outstanding awards will be unwound and cancelled.
• The company will continue discussions regarding potential capital raising options.
• The company will file a Current Report on Form 8-K with the SEC within four business days following the annual meeting to publish the final voting results.
• The company will use commercially reasonable efforts to file a registration statement on Form S-1 (or S-3) for the resale of AmTrust Settlement Shares within 45 days of April 6, 2025 (i.e., prior to May 21, 2025) and cause it to be effective within 60 days thereafter (or by the third business day if no SEC review).

Key Dates

Recommendation

Keywords

Reverse Stock Split, Authorized Share Increase, Nasdaq Listing, Proxy Statement, Corporate Governance, Executive Compensation, Equity Incentive Plan, Shareholder Meeting, SEC Filing, Biotechnology, Pharmaceuticals, Risk Management, Litigation Settlement, Capital Raise, Dilution